lysine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1622 56-87-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • L-Lysine
  • lysine
  • L-(+)-Lysine
  • lysine hydrochloride
  • lysine HCl
An essential amino acid. It is often added to animal feed.
  • Molecular weight: 146.19
  • Formula: C6H14N2O2
  • CLOGP: -3.42
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 3
  • TPSA: 89.34
  • ALOGS: -0.14
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
June 23, 2021 PMDA FUJIFILM TOYAMA CHEMICAL Co., Ltd.
None FDA
July 25, 2019 EMA Advanced Accelerator Applications

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Foetal growth restriction 44.92 19.75 16 3046 7537 63478423
Infantile apnoea 32.69 19.75 8 3054 1025 63484935
Cerebral haemorrhage 28.47 19.75 18 3044 30711 63455249
Selective eating disorder 27.17 19.75 8 3054 2064 63483896
Sinusitis 21.67 19.75 39 3023 226614 63259346

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Vasoplegia syndrome 34.81 27.17 8 714 1848 34954361
Compartment syndrome 30.94 27.17 8 714 3010 34953199
Coma scale abnormal 28.69 27.17 8 714 4000 34952209

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Vasoplegia syndrome 25.38 19.90 8 2746 3622 79738012
Compartment syndrome 22.74 19.90 8 2746 5074 79736560

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B05XB03 BLOOD AND BLOOD FORMING ORGANS
BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
I.V. SOLUTION ADDITIVES
Amino acids
ATC V03AF11 VARIOUS
ALL OTHER THERAPEUTIC PRODUCTS
ALL OTHER THERAPEUTIC PRODUCTS
Detoxifying agents for antineoplastic treatment
CHEBI has role CHEBI:27027 trace elements
CHEBI has role CHEBI:35623 anticonvulsants
CHEBI has role CHEBI:50733 Dietary Supplement
CHEBI has role CHEBI:75771 Mus musculus metabolites
CHEBI has role CHEBI:75772 S. cerevisiae metabolites
CHEBI has role CHEBI:76924 plant metabolites
CHEBI has role CHEBI:76971 Escherichia coli metabolites
CHEBI has role CHEBI:77746 Homo sapiens metabolite
CHEBI has role CHEBI:84735 algal metabolites
CHEBI has role CHEBI:83056 Daphnia magna metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Renal radiation exposure from Lutetium (177Lu) oxodotreotide indication 218190002
Partial Central Diabetes Insipidus indication
Classical phenylketonuria contraindication 7573000
Poisoning by digitalis glycoside contraindication 12876009
Sarcoidosis contraindication 31541009 DOID:11335
End stage renal disease contraindication 46177005 DOID:784
Humoral hypercalcemia of malignancy contraindication 47709007
Heart disease contraindication 56265001 DOID:114
Hypercalcemia contraindication 66931009 DOID:12678
Ventricular fibrillation contraindication 71908006
Hypercalciuria contraindication 71938000
Kidney disease contraindication 90708001 DOID:557
Kidney stone contraindication 95570007




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 1.99 acidic
pKa2 10.46 Basic
pKa3 9.86 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Glutathione reductase, mitochondrial Enzyme Ki 4.26 CHEMBL

External reference:

IDSource
4018682 VUID
N0000146993 NUI
D02304 KEGG_DRUG
657-27-2 SECONDARY_CAS_RN
4018682 VANDF
4018689 VANDF
C0024337 UMLSCUI
CHEBI:25094 CHEBI
LYS PDB_CHEM_ID
CHEMBL8085 ChEMBL_ID
DB00123 DRUGBANK_ID
CHEMBL2105886 ChEMBL_ID
D008239 MESH_DESCRIPTOR_UI
5962 PUBCHEM_CID
6166 INN_ID
724 IUPHAR_LIGAND_ID
K3Z4F929H6 UNII
6536 RXNORM
10705 MMSL
233693 MMSL
40036 MMSL
42619 MMSL
5002 MMSL
d00488 MMSL
000931 NDDF
005151 NDDF
418834008 SNOMEDCT_US
734658000 SNOMEDCT_US
75799006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0180 INJECTION 464 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0180 INJECTION 464 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0184 INJECTION, EMULSION 464 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0184 INJECTION, EMULSION 464 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0188 INJECTION 464 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0188 INJECTION 464 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0194 INJECTION 464 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0194 INJECTION 464 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0198 INJECTION 348 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0198 INJECTION 348 mg INTRAVENOUS NDA 21 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0202 INJECTION 464 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0202 INJECTION 464 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0202 INJECTION 464 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0206 INJECTION 464 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0206 INJECTION 464 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0206 INJECTION 464 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0210 INJECTION 464 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0210 INJECTION 464 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0210 INJECTION 464 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0214 INJECTION 464 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0214 INJECTION 464 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0214 INJECTION 464 mg INTRAVENOUS NDA 20 sections
Travasol HUMAN PRESCRIPTION DRUG LABEL 15 0338-0644 INJECTION 580 mg INTRAVENOUS NDA 20 sections
Travasol HUMAN PRESCRIPTION DRUG LABEL 15 0338-0644 INJECTION 580 mg INTRAVENOUS NDA 20 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1089 INJECTION 247 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1089 INJECTION 247 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1091 INJECTION 247 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1091 INJECTION 247 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1099 INJECTION 290 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1099 INJECTION 290 mg INTRAVENOUS NDA 21 sections